Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Nantes University Hospital |
---|---|
Information provided by: | Nantes University Hospital |
ClinicalTrials.gov Identifier: | NCT00549575 |
Although there is a strong rationale to supplement gravid patients suffering intrauterine growth restriction (IUGR) or preeclampsia with Arginine or other nitric oxide donors, evidence in the literature has been inconclusive. The current study was designed to determine whether oral treatment with L-Arginine, a nitric oxide (NO) donor, would enhance birth weight and/or decrease neonatal morbidity in pregnancies with severe vascular intrauterine growth restriction (IUGR).
Condition | Intervention | Phase |
---|---|---|
Intra Uterine Growth Retardation |
Drug: L ARG Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial |
Enrollment: | 44 |
Study Start Date: | July 2000 |
Study Completion Date: | June 2006 |
Arms | Assigned Interventions |
---|---|
A: Experimental
Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories). Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
|
Drug: L ARG
Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories).
|
B: Placebo Comparator
After double blind randomization, patients received a placebo. Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
|
Drug: Placebo
After double blind randomization, patients received a placebo.
|
Patients and Methods: 44 patients with a singleton pregnancy who had been referred for IUGR detected by ultrasonic examination were included. Vascular IUGR was defined by fetal abdominal circumference less than or equal to the third percentile, associated with abnormal uterine Doppler. After double blind randomization, patients received either 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories), or a placebo. Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venosus was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
France | |
CHU-NANTES | |
NANTES, France, 44093 |
Principal Investigator: | Norbert Winer, Doctor | CHU NANTES |
Study Chair: | Dominique Darmaun, Professor | CHU NANTES |
Study Chair: | Philippe Gilard, Doctor | CHU ANGERS |
Study Chair: | F Goffinet, Professor | Paris-Port-Royal |
Study ID Numbers: | 99/4-A |
Study First Received: | October 24, 2007 |
Last Updated: | October 25, 2007 |
ClinicalTrials.gov Identifier: | NCT00549575 History of Changes |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
Severe Intra uterine growth retardation below the third centile with abnormal uterine doppler Severe growth retardation with pathologic uterine Doppler L-Arginine Nitric Oxide Donor Severe Intra uterine growth retardation below the third centile with abnormal uterine doppler |
Nitric Oxide Fetal Diseases Pregnancy Complications Arginine |
Growth Disorders Fetal Growth Retardation Nitric Oxide Donors |
Fetal Diseases Pathologic Processes Pregnancy Complications Growth Disorders Fetal Growth Retardation |